SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

9815	Companies
196953	Keywords
128003	Articles
104734	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/24/2025 at 04:36, 7 months 12 days ago

Sanofi : Déclaration des transactions sur actions propres
BRIEF

published on 06/23/2025 at 07:05, 7 months 13 days ago

Sarclisa obtient une recommandation de l'UE pour le traitement du myélome multiple

Myélome Multiple Étude De Phase 3 Sarclisa Approbation Du CHMP Thérapie D'induction
BRIEF

published on 06/23/2025 at 07:05, 7 months 13 days ago

Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment

Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
PRESS RELEASE

published on 06/23/2025 at 07:00, 7 months 13 days ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
PRESS RELEASE

published on 06/23/2025 at 07:00, 7 months 13 days ago

Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple. Recommandation basée sur l'étude de phase 3 GMMG-HD7 montrant amélioration significative de la SSP

Myélome Multiple Approbation Sarclisa CHMP GMMG-HD7
BRIEF

published on 06/20/2025 at 07:05, 7 months 16 days ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease
BRIEF

published on 06/20/2025 at 07:05, 7 months 16 days ago

La FDA approuve le Dupixent pour le traitement de la pemphigoïde bulleuse

Approbation De La FDA Dupixent Pemphigoïde Bulleuse Inflammation De Type 2 Maladie Cutanée Rare
PRESS RELEASE

published on 06/20/2025 at 07:00, 7 months 16 days ago

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse
Dupixent approuvé par la FDA aux États-Unis pour traiter la pemphigoïde bulleuse, offrant une nouvelle approche ciblée contre l'inflammation de type 2. Résultats positifs de l'étude ADEPT

FDA Dupixent Pemphigoïde Bulleuse Inflammation De Type 2 Étude ADEPT
PRESS RELEASE

published on 06/20/2025 at 07:00, 7 months 16 days ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine for bullous pemphigoid, meeting the critical treatment needs of patients with uncontrolled disease

FDA Approval Chronic Disease Dupixent Type 2 Inflammation Bullous Pemphigoid
BRIEF

published on 06/17/2025 at 13:45, 7 months 18 days ago

Sanofi Successfully Prices €1.5 Billion Bond Issue

Bond Issue Corporate Financing Sanofi Fixed-rate Notes Euro Medium Term Note

Accesswire

Published on 02/06/2026 at 08:00, 1 hour 5 minutes ago

Caledonia Mining Corporation Plc Non-Executive Director Shareholding Notification
Published on 02/06/2026 at 03:50, 5 hours 15 minutes ago

High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 02:45, 6 hours 20 minutes ago

High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 00:57, 8 hours 8 minutes ago

Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 9 hours 5 minutes ago

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

View all ACCESSWIRE

EQS Group

Published on 02/06/2026 at 08:15, 50 minutes ago

Bechtle posts strong year-end performance
Published on 02/06/2026 at 08:00, 1 hour 4 minutes ago

A stronger and more competitive Ørsted after a defining year with earnings of DKK 25.1 billion within guidance
Published on 02/06/2026 at 08:00, 1 hour 4 minutes ago

Transaction in Own Shares
Published on 02/06/2026 at 08:00, 1 hour 4 minutes ago

BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS INC., FILIALE DE BIOSYNEX, REÇOIT UNE SUBVENTION DE $1,8 MILLION DE CARB-X POUR LE DÉVELOPPEMENT D'UN TEST DE DIAGNOSTIC RAPIDE DE LA FIEVRE TYPHOIDE
Published on 02/06/2026 at 07:30, 1 hour 34 minutes ago

Nordex Group wins multiple European contracts totaling 220 MW in January 2026

Les Echos

Published on 02/06/2026 at 07:54, 1 hour 10 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026
Published on 02/05/2026 at 19:24, 13 hours 40 minutes ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 19:24, 13 hours 40 minutes ago

Compte-Rendu de l’Assemblée Générale Mixte
Published on 02/05/2026 at 19:15, 13 hours 50 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 13 hours 50 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026

View all LES ECHOS COMFI WIRE